PVP K-Series (povidone) pharma grade is a linear, water-soluble polymer of N-vinylpyrrolidone supplied as a white to off-white hygroscopic powder with model designations K-12, K-17, K-25, K-30, and K-90. The K-value is a Fikentscher viscosity index calculated from relative viscosity in water at 25 °C using an Ubbelohde capillary viscometer per USP〈911〉 and Ph. Eur. 2.2.9; it is not an absolute molar mass. Weight-average molar mass rises from 2,000–3,000 g/mol for K-12 to 1,000,000–1,500,000 g/mol for K-90, and the dynamic viscosity of a 10% w/v aqueous solution rises from 1.5–2.5 mPa·s to 300–700 mPa·s over the same series. This product is applied as a binder, film former, stabiliser, and solubility-enhancing carrier in tablet, capsule, granule, oral liquid, and injectable processing.

Because K-Series polymers are hygroscopic, equilibrium moisture at 75% RH reaches approximately 28% by mass for K-30. That water uptake directly affects flow and compaction: bulk powder with moisture above 5.0% may exhibit reduced glass transition and increased sticking on rotary tablet tooling. Consequently, grade selection and storage conditions are not independent variables; a K-30 batch stored in an open hopper at 60% RH can exceed the pharmacopeial water limit within 8–12 h in the absence of moisture-controlled handling.

Polymerisation is controlled to limit residual vinylpyrrolidone monomer to ≤10 ppm; free-radical initiators are selected from thermal azo or peroxide systems, but final peroxide content is reduced by post-polymerisation treatment such as vacuum stripping or addition of sodium sulfite. The resin is then spray-dried from aqueous solution to yield spherical agglomerates with low dusting and controlled particle size. These process choices affect aldehyde formation: aldehyde content above 500 ppm as acetaldehyde can originate from oxidative degradation during drying and is controlled by nitrogen blanketing and low-residence-time dryers.

What Separates K-12, K-30, and K-90 in Solid Oral Dosage Manufacturing?

The K-Series grades are differentiated by rheological and film-forming properties that control unit-operation suitability. K-12 and K-17 have low-viscosity solutions and are routinely specified for injectable and oral liquid stabilisation, whereas K-30 is the standard wet-granulation binder for lactose, mannitol, and dicalcium phosphate formulations at 2–5% w/w of the dry mix. K-90 is selected when high solution viscosity reduces drug migration during drying and improves low-dose content uniformity, but the 300–700 mPa·s viscosity of a 10% w/v solution restricts spray delivery to dilute systems of 2–3% w/w.

The difference from crospovidone is operationally significant. Crospovidone is an insoluble, cross-linked polyvinylpyrrolidone that acts as a superdisintegrant at 2–5% w/w by wicking and swelling, while the K-Series dissolves completely in water, ethanol, and isopropanol. A tablet bound with K-30 but without crospovidone or sodium starch glycolate at 2–4% w/w may fail disintegration requirements because the soluble binder hydrates to a tacky film rather than creating liquid channels. Similarly, copovidone (60:40 vinylpyrrolidone–vinyl acetate) is a separate polymer with lower hygroscopicity and is preferred for moisture-sensitive actives, but it does not match the aqueous binding capacity of K-90 at equivalent solids.

Published values in the table represent typical data from pharmacopeial and manufacturer technical bulletins; individual grades may vary within the allowed K-value window. The inhalation or parenteral route should not use non-injection grade K-Series unless endotoxin and particulate controls are verified.

Specification Compliance Under USP–NF and Ph. Eur. Monographs

Pharmacopeial release of K-Series povidone typically follows the USP–NF Povidone monograph, Ph. Eur. 0685, and JP XVIII. The following matrix lists representative acceptance limits for K-30; K-12 and K-17 differ principally in K-value and viscosity specification.

For injectable grade, the specification is extended with bacterial endotoxins <0.2 EU/mg per USP〈85〉/Ph. Eur. 2.6.14, total aerobic microbial count ≤100 CFU/g, and absence of Escherichia coli per Ph. Eur. 5.1.4. Packaging in nitrogen-flushed aluminium foil laminate with desiccant is used because peroxides and aldehydes are storage-dependent; warehouse storage at 15–25 °C and ≤60% RH in unopened containers is specified. Opened bulk containers should be re-sealed under nitrogen and used within 72 h to limit moisture uptake and peroxide formation.

Commercial pharma grades are available as fine powder with D50 near 50–70 µm and as standard granular material with D50 near 120–180 µm. The fine grade is preferred for dry mixing and tablet binding due to faster dissolution, while the granular grade reduces dusting in direct-compression operations. Bulk density typically falls between 0.45–0.55 g/mL for K-30 fine and 0.40–0.50 g/mL for K-90; tapped density is approximately 0.55–0.70 g/mL, giving compressibility indices 10–20% and acceptable flow in force-fed hoppers.

Injectable applications require low-endotoxin and low-peroxide material because residual peroxides can oxidise oxygen-sensitive actives and increase subvisible particle counts after terminal sterilisation. K-12 and K-17 are typically dissolved at 0.5–2.0% w/v in Water for Injection before addition of the active; the low viscosity permits filtration through a 0.22 µm PVDF or PES membrane at 10–20 °C under a differential pressure of ≤1.5 bar. In lyophilised products, K-12 at 2–5% w/w of cake solids acts as a cryoprotectant and bulking agent, reducing collapse and yielding a cake with residual moisture below 1.0% after primary drying at shelf −20 °C and secondary drying at 40 °C for 6 h. Injection-grade powder should be pre-dried to <2.0% water before compounding if held outside a nitrogen-purged container for more than 72 h; vacuum drying at 50 °C/10 mbar for 4–6 h or fluid-bed drying at 60 °C is typical. Subvisible particulate matter should be confirmed after filtration to meet USP〈787〉/Ph. Eur. 2.9.19 limits of ≤6,000 particles/container ≥10 µm and ≤600 particles/container ≥25 µm for small-volume parenterals.

In oral solutions and syrups, K-30 at 1–5% w/v is applied as a viscosity modifier and dye stabiliser. Povidone is not a preservative; it can bind phenolic preservatives and may reduce preservative activity, so a preservative efficacy test per USP〈51〉 should be performed at the final polymer concentration if parabens or benzoic acid are present. K-90 is less suitable for elegant syrups above 2% w/v because its high viscosity produces stringy rheology and air entrapment in filling lines; K-25 or K-30 are preferred when low-shear viscosity must remain below 50 mPa·s at filling temperatures of 20–25 °C.

When Povidone K-30 Replaces Hypromellose in Aqueous Film Coating and Granulation

Film-coating and binder operations make use of K-30 at 5–10% w/w in aqueous or hydroalcoholic solutions. The low surface tension of K-30 solutions (≈55–65 mN/m at 20 °C for 5% w/w) improves substrate wetting but increases tack during pan coating; inlet air should be maintained at 60–70 °C and exhaust relative humidity ≤20% to avoid picking. When replacing hypromellose in an immediate-release coating at 2–3% weight gain, K-30 produces a clear, water-soluble film without thermal gelation, but the film is more hygroscopic and may require 0.5–1.0% w/w talc or glycerol monostearate as anti-tack agent. Unlike hypromellose, which forms a gel network at 60–65 °C, K-30 solution viscosity decreases with temperature, allowing sustained sprayability from ambient to 60 °C. This thermal distinction also affects dissolution testing: K-30 films do not create a gel layer that retards drug release in 0.1 M HCl at 37 °C, so release remains erosion-controlled and immediate unless a K-90 matrix is added at 20–40% w/w.

Mixer Torque, Granule Size Distribution, and Dissolution Limits

On a 25 L Diosna P/VAC-25 or equivalent high-shear granulator, K-30 wet granulation of dicalcium phosphate/lactose blends reaches a wet mass endpoint at impeller speed 200–300 rpm, chopper speed 1,500 rpm, and torque 8–12 N·m; binder solution is introduced through a peristaltic pump at 0.5–1.0 L/min. Wet granules discharged through a 1.0 mm mesh and dried in a fluid-bed dryer with inlet air 60–65 °C to product moisture 1.5–2.5% produce granule D50 100–250 µm and angle of repose 25–35°. Tablets compressed on a 16-station rotary press to hardness 60–120 N for 10 mm concave tooling show friability <1.0% per USP〈1216〉 and disintegration <15 min in 0.1 M HCl at 37 °C per USP〈701〉. For hard capsules, the same granules filled to weight RSD <3% meet content uniformity if K-30 is present at 3–5% w/w and the D90/D10 ratio remains below 3.0 to minimise segregation in the powder hopper.

For capsule filling, K-30 binder solution at 3–5% w/w is preferred to dry addition because wet-granulated granules provide denser, free-flowing particles for dosator and tamping-pin machines. Granules with bulk density 0.50–0.60 g/mL and Carr index 10–15% fill size 0 and size 1 capsules with weight variation below 2% RSD. K-90 at 2–4% w/w can be used in sustained-release granule matrices, but wet mass viscosity must be monitored to avoid granulator overload.

For solubility enhancement, K-30 and K-90 are processed at polymer-to-drug ratios of 2:1 to 5:1 in spray-dried and hot-melt-extruded amorphous solid dispersions. The glass transition temperature of K-30 is approximately 163 °C; K-90 exhibits a Tg near 180 °C. Processing above 180 °C increases the risk of pyrrolidone ring-opening and discolouration, so hot-melt extrusion is usually limited to a barrel set point of 150–170 °C with a residence time of 2–5 min. Spray drying from methanol or acetone at inlet temperature 80–120 °C with feed solids 10–20% w/w yields amorphous dispersions with residual solvent below ICH Q3C Option 2 limits after secondary vacuum drying at 50 °C for 12 h. Both grades inhibit drug recrystallisation through hydrogen bonding, but K-90 often provides a longer physical stability window at the cost of higher melt viscosity and reduced process throughput.

Povidone interacts with phenolic APIs, tannins, and some preservatives through hydrogen bonding and hydrophobic association; dissolution of acidic drugs may be retarded if a K-90 matrix is used above 10% w/w. For low-dose actives, a 0.5–1.0% w/w K-30 solution as a carrier during wet granulation reduces segregation but does not serve as a substitute for geometric dilution. Published data for specific low-dose API blend configurations is limited; process compatibility should be confirmed by forced degradation and dissolution testing.

Storage and incompatibility boundaries are critical. Povidone should not be processed with strong oxidizing agents such as hypochlorite or permanganate, and strongly alkaline buffers may promote ring-opening and aldehyde formation. In aqueous systems containing primary amines, heat sterilisation can accelerate Maillard-type reactions and discolouration; therefore, amine-bearing actives require segregation from povidone in liquid formulations or use of a low-aldehyde grade. K-Series is also not interchangeable with poloxamer or PEG as a cryoprotectant in lyophilisation because each polymer exerts different vitrification and ice-crystal inhibition mechanisms. For formulations requiring enteric resistance, K-30 is used only as a subcoat or binder; it dissolves rapidly in gastric fluid and does not provide pH-dependent release.